GlassScriptPhysician profile
Rajeev H Mehta
NPI 1891778718
$12,026.80
in general payments reported to CMS, 2019-2025
24 companies · $954 in 2025
The $954 reported for 2025 was more than what 78% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,771 · 2020: $3,649 · 2021: $484 · 2022: $772 · 2023: $1,016 · 2024: $2,382 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,133 · Travel and Lodging: $1,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,132.90 |
| Travel and Lodging | $1,218.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,076.79 | 2019-2022 | |
| Inspire Medical Systems, INC. | $3,119.32 | 2021-2025 | Inspire |
| Medtronic, INC. | $374.20 | 2021-2024 | Propel, Pteye Parathyroid Detection System |
| Aerin Medical INC. | $373.40 | 2022-2023 | |
| Acclarent, INC | $350.28 | 2019-2023 | Trudi Nav Cable |
| Stryker Corporation | $319.60 | 2019-2025 | Scopis Ent |
| Optinose US, INC. | $239.70 | 2020-2025 | |
| Intersect Ent, INC. | $196.25 | 2019-2020 | |
| Glaxosmithkline, LLC. | $190.99 | 2022-2025 | Nucala |
| Watermark Medical, INC. | $142.65 | 2022 | |
| Genzyme Corporation | $120.08 | 2022-2025 | |
| Boston Scientific Corporation | $104.60 | 2021 | |
| Elutia, INC. | $80.95 | 2024 | Ecm Patch,Pouch |
| Janssen Pharmaceuticals, INC | $62.69 | 2022 | |
| Neurent Medical Limited | $59.44 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $44.45 | 2020 | |
| Alk-Abello, INC | $37.21 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $29.90 | 2024 | Dupixent |
| Merck Sharp & Dohme LLC | $27.98 | 2025 | Keytruda |
| Smith+Nephew, INC. | $24.23 | 2024 | |
| Integra Lifesciences Corporation | $14.94 | 2019 | |
| Ethicon US, LLC | $13.62 | 2019 | |
| Hikma Pharmaceuticals USA | $12.36 | 2022 | |
| Olympus America INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.